Search Results

YDS Pharmatech, Inc., a pioneering innovator at a transformative juncture in applying AI to drug discovery, announces its participation in this year’s Bio Investor Forum.

D&D Pharmatech, Inc., a clinical-stage biotechnology company focused on the development of disease-modifying drugs, announced that the U.S. Food and Drug Administration has granted Fast Track designation for the investigation of DD01 for the treatment of adults with non-alcoholic steatohepatitis, also known as metabolic dysfunction-associated steatohepatitis.

Pharmatech Associates, a subsidiary of the United States Pharmacopeia, announced it has appointed the biotech expert Dr. Praveen Tyle to its board of trustees.

Recently, Crystal Formulations Services, the CDMO Business Unit of Crystal Pharmatech has achieved a significant milestone by successfully passing the on-site audit conducted by the European Qualified Person, evaluating its GMP quality system and production facilities.

This week at CPHI Barcelona, Pharmatech Associates will showcase its expertise and capabilities that help global pharmaceutical and emerging biotech companies accelerate their innovation and speed delivery of breakthrough medicines and therapies to patients.

YDS Pharmatech, Inc., announced that it is presenting at Biotech Showcase™ 2023.

YDS Pharmatech today announced the appointment of Dr. Robert Sullivan as Head of Medicinal Chemistry.